Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of mannan-oligosaccharide aldehyde acid salt in preparing medicine for preventing and curing liver damage, various hepatitis, liver fibrosis or cirrhosis

A technology of mannuronic acid and uronic acid salt, which is applied in the direction of drug combination, digestive system, and pharmaceutical formula, can solve problems that have not yet been seen, and achieve the effects of broad development and application prospects, abundant resources, and easy industrialization

Active Publication Date: 2014-08-06
MARINE BIOMEDICAL RES INST OF QINGDAO CO LTD
View PDF6 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are reports at home and abroad that oligomannuronic acid has various biological activities such as anti-oxidation, anti-inflammation, immune regulation, and anti-senile dementia. Reports on hepatitis, liver fibrosis and liver cirrhosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mannan-oligosaccharide aldehyde acid salt in preparing medicine for preventing and curing liver damage, various hepatitis, liver fibrosis or cirrhosis
  • Application of mannan-oligosaccharide aldehyde acid salt in preparing medicine for preventing and curing liver damage, various hepatitis, liver fibrosis or cirrhosis
  • Application of mannan-oligosaccharide aldehyde acid salt in preparing medicine for preventing and curing liver damage, various hepatitis, liver fibrosis or cirrhosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Embodiment 1: Preparation of oligomannuronate (LPM)

[0027] Prepare alginate (sodium alginate in this example) into a 10wt% aqueous solution, heat it to 80-90°C with 1wt% dilute hydrochloric acid, stir and degrade it for 4-5 hours, neutralize it with 10wt% sodium carbonate aqueous solution after cooling, and then Use 5wt% dilute hydrochloric acid to adjust the pH to about 3.65, centrifuge to collect the supernatant, then add 3 times the volume of 95wt% medical ethanol, collect the precipitate, dehydrate with absolute ethanol and dry to obtain polymannuronic acid (Mw=10.6kD). The polymannuronic acid is prepared into aqueous solutions of different concentrations with pure water, which are added to a microwave digestion tank for microwave degradation for 5, 10, 15, 20, and 30 minutes to obtain oligomeric mannuronic acids with different molecular weights. Lithium and sodium salts of oligomannuronic acid with different molecular weights can be obtained by ultrafiltration an...

Embodiment 2

[0032] Example 2: Oligomannuronate (LPM) to CCl 4Inhibitory effect of induced increase in mouse liver body mass index

[0033] The present embodiment adopts the oligomeric mannuronic acid sodium salt obtained in Example 1. Sixty Kunming mice of 18-22 g were randomly divided into normal (control) group, model group, positive drug (bifendate) group and LPM (Mr=3.2kD) administration group, 15 in each group. Adaptive feeding for 3 to 5 days. During the experiment, the mice were free to eat common feed and drinking water. One dose of 100 mg / kg was given once, and 0.35 wt% CCl was given once 1 hour later. 4 10ml / kg, fasting without water. After 16 hours, the mice were sacrificed, the liver was separated, rinsed twice with pre-cooled PBS (0.1M, pH=7) solution, and then the water on the surface of the organ was blotted dry with filter paper, weighed, and the organ index was calculated. The calculation formula is as follows: organ index (%)=organ weight (g) / body weight (g)*100%, and...

Embodiment 3

[0038] Example 3: Oligomannuronate vs. CCl 4 Inhibition of induced increase in serum ALT and AST levels in mice

[0039] The present embodiment adopts the oligomeric mannuronic acid sodium salt obtained in Example 1. Sixty Kunming mice of 18-22 g were randomly divided into normal (control) group, model group, positive drug (bifendate) group and LPM (5.8kD) administration group, 15 in each group. Adaptive feeding was carried out for 3 to 5 days. During the experiment period, the mice were free to eat common feed and drinking water. One dose of 100 mg / kg was given once, and 1 hour later, 0.35 wt% CCl4 10 ml / kg was given once. After 16 hours, the mice were killed, blood was collected from the eyeballs, serum was prepared at 3000 rpm×10 min, and ALT and AST indexes were measured. The experimental results are shown in Table 2.

[0040] Table 2 Oligomannuronate to CCl 4 Inhibitory effect of ALT, AST level increase

[0041] group

Dose (mg / kg)

ALT(U / L)

AST(U / L...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Weight average molecular weightaaaaaaaaaa
Weight average molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of marine drugs and particularly relates to the application of mannan-oligosaccharide aldehyde acid salt in preparing a medicine for preventing and curing liver damage, various hepatitis, liver fibrosis or cirrhosis. The mannan-oligosaccharide aldehyde acid salt is used for preparing the medicine for protecting livers and curing various hepatitis, liver fibrosis or cirrhosis. The mannan-oligosaccharide aldehyde acid salt takes algin as a raw material, through a chemical degradation method or a physical degradation method, or the combination of the two degradation methods, mannan-oligosaccharide aldehyde acid with different molecular weights can be obtained; the mannan-oligosaccharide aldehyde acid is prepared through neutralization into lithium salt, sodium salt, kali salt, calcium salt or magnesium salt of the mannan-oligosaccharide aldehyde acid with different molecular weights, the molecular skeleton of the mannan-oligosaccharide aldehyde acid adopts a linear oligosaccharide compound formed by connecting D-mannuronic acid (M) through a Beta-1, 4 glucosidic bond. The product in the invention is derived from algal polysaccharides, has the advantages of rich resources, easiness in industrialization, safety, effectiveness and the like, and has a wide development and application prospect in preventing and curing liver damage, and various hepatitis, liver fibrosis and cirrhosis.

Description

technical field [0001] The invention belongs to the field of marine medicines, and in particular relates to the application of an oligomannuronic acid salt in the preparation of medicines for preventing and treating liver damage and various hepatitis, liver fibrosis or liver cirrhosis. Background technique [0002] As one of the largest and most functional substantive glandular organs in the human body, the liver is known as "the largest chemical factory in the human body". The liver participates in digestion, metabolism, excretion, detoxification and immunity in the body. The high incidence of development, environmental pollution, and food and drug safety incidents has led to an increasing trend in the incidence of diseases that cause liver function damage year by year. Studies have shown that liver lesions are diverse and refractory. At present, the treatment methods for liver diseases mainly include etiological treatment, diet therapy and drug therapy, and there is no ve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/715A61K31/702A61K31/7016A61P1/16A61P31/12
Inventor 郝杰杰管华诗于广利胡婷敦云楼周晓琳夏萱
Owner MARINE BIOMEDICAL RES INST OF QINGDAO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com